Compare · CVII vs EUCR
CVII vs EUCR
Side-by-side comparison of Churchill Capital Corp VII (CVII) and Eucrates Biomedical Acquisition Corp. (EUCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVII and EUCR operate in Blank Checks (Finance), so they compete in similar markets.
- CVII is the larger of the two at $1.68B, about 12.7x EUCR ($131.6M).
Churchill Capital Corp VII
Churchill Capital Corp VII focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
Eucrates Biomedical Acquisition Corp.
Eucrates Biomedical Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest CVII
- Amendment: SEC Form SC 13G/A filed by Churchill Capital Corp VII
- SEC Form 15-12G filed by Churchill Capital Corp VII
- Large owner Magnetar Financial Llc disposed of $90,084,438 worth of shares (8,306,005 units at $10.85) (SEC Form 4)
- Churchill Capital Corp VII filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form 25-NSE filed by Churchill Capital Corp VII
- Churchill Capital Corp VII and CorpAcq Mutually Agree to Terminate Business Combination
- SEC Form 10-Q filed by Churchill Capital Corp VII
- Churchill Capital Corp VII filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Churchill Capital Corp VII
- SEC Form DEFA14A filed by Churchill Capital Corp VII
Latest EUCR
- SEC Form 15-12G filed by Eucrates Biomedical Acquisition Corp.
- SEC Form 25-NSE filed by Eucrates Biomedical Acquisition Corp.
- SEC Form 10-K filed by Eucrates Biomedical Acquisition Corp.
- Reported Late Tuesday April 11, Eucrates Biomedical Acquisition Corp. Announces Liquidation; Co To Redeem All Outstanding Shares At A Per-Share Redemption Price Of ~$10
- Eucrates Biomedical Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Eucrates Biomedical Acquisition Corp. Announces Liquidation
- Eucrates Biomedical Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation
- SEC Form NT 10-K filed by Eucrates Biomedical Acquisition Corp.
- Eucrates Biomedical Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form SC 13G/A filed by Eucrates Biomedical Acquisition Corp. (Amendment)